A drug does not have a regulatory system as one document. Behind every approved drug are a myriad of interconnected information points covering the product’s details, manufacturing data as well as clinical evidence and safety information, as well as labels, regulatory submission services and lifecycle modifications.
When products are expanded across markets, the information is governed by different teams, systems and processes for regulating. If there isn’t a strong governance system even slight inconsistencies can result in significant regulatory challenges. A difference in product information between submissions, variations, labeling documents, or regulatory databases may appear minor.
However, regulators evaluate product information as a connected regulatory record, where accuracy, consistency, and traceability are essential, this is why Regulatory Data Quality has become a critical compliance consideration for pharmaceutical companies.
Regulatory success is no longer dependent only on preparing accurate documents. It increasingly depends on maintaining reliable, structured, and consistent regulatory information throughout the product lifecycle.
Why Regulatory Data Quality is Becoming a Compliance Issue
The pharmaceutical regulatory environment is becoming increasingly complex.
Companies are managing:
- Multiple global markets
- Different regulatory requirements
- Increasing product lifecycle activities
- Growing electronic submission expectations
- More structured regulatory data requirements
Historically, regulatory operations were largely document focused. Today, regulators and pharmaceutical companies are moving toward a more data-driven approach where information must be accurate, structured, reusable, and traceable.
Regulatory authorities are increasingly focused on improving the quality and consistency of data used in regulatory decision-making. The EMA Data Quality Framework for EU medicines regulation highlights the importance of consistent and standardised approaches to assessing data quality to support reliable regulatory decisions. For pharmaceutical companies, this means regulatory information cannot be managed as isolated documents. It must be managed as a connected information ecosystem, as here effective regulatory data management becomes essential.
What Happens When Product Information is Inconsistent?
Product information is used across multiple regulatory activities, including:
- Marketing authorisation applications (MAA)
- Variations and post-approval submissions
- Safety updates
- Labeling changes
- Regulatory commitments
- Global product registrations
When information is inconsistent, the impact can extend beyond administrative correction.
These inconsistencies can create:
- Additional regulatory questions
- Review delays
- Submission rework
- Increased operational burden
- Potential compliance concerns
A regulator reviewing a submission expects confidence that the information represents one accurate and controlled version of the product. Poor data quality can reduce that confidence.
Where Does Poor Regulatory Data Come From?
Poor regulatory data rarely develops from a single mistake, it usually results from a combination of process, technology, and governance challenges.
Common sources include:
Disconnected systems
Many organisations use multiple platforms for:
- Regulatory submissions
- Document management
- Safety information
- Labeling
- Product data
- Manufacturing information
When systems do not communicate effectively, inconsistencies can develop.
Manual data management processes
Manual updates increase the possibility of:
- Duplicate information
- Incorrect versions
- Missed updates
- Data entry errors
As product portfolios expand, manual processes become increasingly difficult to control.
Lack of ownership and governance
Regulatory data often involves multiple stakeholders:
- Regulatory affairs
- Quality
- Safety teams
- Clinical functions
- Manufacturing teams
- Commercial teams
Without clear ownership, responsibility for data accuracy can become unclear.
Poor lifecycle control
A product’s regulatory information changes continuously. New approvals, variations, safety updates, and labeling changes must be reflected consistently across systems. Without strong Post Approval Life cycle Management, outdated information can remain active in regulatory processes.
How Inconsistent Product Data Creates Submission Risk
A regulatory submission is only as reliable as the information supporting it. During submission preparation, inconsistent product data can create challenges such as:
- Incorrect product information in applications
- Differences between current and proposed labeling
- Misalignment between regulatory modules
- Missing supporting information
- Additional authority questions
A product may be registered in multiple regions, each with different regulatory requirements and timelines. Maintaining consistency across markets requires controlled processes and reliable data management.
A strong regulatory information management system (RIMS) helps organisations centralise, govern, and maintain regulatory information throughout submission activities. However, technology alone does not solve data quality issues. The system is only as effective as the quality and governance of the information it manages.
How Poor Product Data Creates Lifecycle and Compliance Risk
Regulatory obligations continue long after product approval. Once a medicine reaches the market, companies must manage ongoing activities including:
- Safety updates
- Labeling changes
- Variations
- Renewals
- Regulatory commitments
- Market expansions
This makes Post Approval Lifecycle Management a critical area where data quality directly influences compliance.
Poor product data can lead to:
- Incorrect regulatory submissions
- Delayed implementation of approved changes
- Inconsistent product information across markets
- Increased regulatory oversight
- Difficulty tracking product history
A product’s regulatory record must remain accurate throughout its entire lifecycle. Approval is not the end of regulatory data management; it is the beginning of continuous regulatory information maintenance.
Why IDMP, ePI and Structured Regulatory Data Change the Game
The regulatory industry is moving from document-centric processes toward structured, data-driven regulatory management. Initiatives such as IDMP and electronic Product Information (ePI) reflect this shift.
Structured regulatory data enables organisations to:
- Improve consistency
- Reduce duplication
- Increase traceability
- Support automation
- Improve information exchange
The EMA and European medicines regulatory network continue developing structured approaches for electronic product information and product data management. The EU ePI initiative focuses on creating harmonised electronic product information that improves accessibility, searchability, and interoperability.
The transition toward structured data requires pharmaceutical companies to strengthen:
- Data governance
- Data standards
- Data ownership
- Information quality controls
For organisations operating in RIM pharma, this shift represents an opportunity to improve regulatory efficiency while reducing compliance risk.
A Regulatory Data Quality Framework for Pharma Companies
A strong Regulatory Data Quality framework should combine people, processes, technology, and governance.
A practical approach includes:
- Data ownership
Clearly define who is responsible for regulatory information accuracy.
Ownership should exist across:
- Product information
- Regulatory attributes
- Labeling data
- Submission content
- Lifecycle updates
- Data standardisation
Companies should establish consistent:
- Terminology
- Data structures
- Product identifiers
- Regulatory attributes
Standardisation improves consistency across regions and systems.
- Data validation controls
Organisations should implement controls to identify:
- Missing information
- Duplicate records
- Incorrect values
- Outdated content
- Inconsistent product data
- Integrated regulatory systems
A strong regulatory information management system should support:
- Centralised information management
- Controlled workflows
- Data traceability
- Lifecycle visibility
- Continuous monitoring
Regulatory data quality should not be assessed only before submission. It should be continuously monitored throughout the product lifecycle.
Regulatory Data Quality Should Be Managed as a Business-Control Issue
Regulatory data is not only a regulatory affairs responsibility.
It influences:
- Market access
- Product launches
- Compliance readiness
- Operational efficiency
- Business decision-making
Poor regulatory data can create hidden costs through:
- Submission delays
- Manual corrections
- Increased review cycles
- Operational inefficiencies
High-quality regulatory data creates strategic value. It enables faster decision-making, improves submission confidence, and supports consistent product information across global markets. For pharmaceutical companies, Regulatory Data Quality should be viewed as a business-control function that protects both compliance and commercial objectives.
How DDReg Supports Regulatory Data Quality and Information Management
Managing regulatory information effectively requires more than implementing a system. Companies need regulatory expertise, data governance, and lifecycle understanding.
DDReg supports pharmaceutical organisations through:
- Regulatory data quality assessment
- Regulatory information management strategy
- RIM implementation support
- Product information review
- Data governance framework development
- Lifecycle management support
- The readiness for regulatory compliance
Combining regulatory expertise and structured data management strategies, DDReg assists organizations in identifying information gaps, increase coherence, and improve the effectiveness of regulation.
The goal is not just to keep track of regulatory information It is also to ensure that the information pertaining to regulatory requirements is reliable, accurate and up to date for each phase of the lifecycle of the product.
Conclusion
Regulatory Data Quality Is the Foundation of Regulatory Confidence
Pharmaceutical companies are dealing with ever more complex regulatory environments, where accuracy of information is crucial. A product’s submission may be scientifically sound, however inconsistency in the information provided can lead to ineffective regulatory hurdles. The future of the regulatory process will depend on advancing beyond document management to intelligent organized, structured and controlled regulation data administration. Regulation Data Quality is not just about avoiding errors, it’s also about building trust in submissions, compliance actions and throughout the life cycle of a product. Pharmaceutical companies need high-quality regulatory information is no longer an option it’s a prerequisite to ensure that regulatory decisions are made with confidence.
Frequently Asked Questions
Regulation data management can help pharmaceutical companies to maintain the same and controlled information about their products throughout submissions and systems and international markets.
Inconsistent information on products can result in submission delays, regulatory queries in the form of incorrect updates and issues in lifecycle management.
IDMP along with ePI initiatives aid in the transition to structured information on regulatory requirements increasing accessibility, consistency and interoperability of the information about products.